A New Test May Help Tell Parkinson’s Apart from Other Similar Conditions

When someone is told they might have Parkinson’s, the diagnosis isn’t always clear-cut. There are other conditions that look like Parkinson’s—such as Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Syndrome (CBS)—but which behave differently and often progress faster. These are called “atypical parkinsonian disorders” (APDs), and telling them apart from Parkinson’s can be difficult, especially early on. But scientists may have found a way to make this job much easier—and it only takes a sample of fluid from your body. What’s This Test All About? A protein called neurofilament light chain (NfL) has caught the attention of researchers. It’s found in nerve cells, and when these cells are damaged (as they are in Parkinson’s and other brain conditions), more NfL leaks into the fluid around the brain and spine (called cerebrospinal fluid or CSF) and even into the blood. In this new study, scientists tested over 500 people who either had Parkinson’s or an atypical form of it. They measured the amount of NfL in both CSF and blood using different testing methods. They also used another test called α-synuclein RT-QuIC, which detects the faulty protein often seen in people with Parkinson’s. What Did They Find? People with atypical Parkinson’s disorders had much higher levels of NfL than those with typical Parkinson’s. Testing CSF gave slightly better results than blood tests, but both were useful. Combining the NfL test with the α-synuclein test gave extremely accurate results—correctly identifying the right diagnosis about 97% of the time. What Does This Mean for People with Parkinson’s? Getting the diagnosis right is crucial. Parkinson’s tends to progress more slowly and responds better to medication. Atypical parkinsonian conditions usually move faster, have different symptoms, and may not respond as well to standard Parkinson’s treatments. This test can help: People get the right diagnosis sooner. Doctors make better treatment plans, tailored to the actual condition. Reduce confusion and emotional strain for people and families who are stuck in diagnostic limbo. And since the blood test version of NfL is easier and less invasive than a spinal tap (used to collect CSF), it brings hope that this might become a routine test in future clinics. Bottom Line This research gives real hope that clearer answers are on the horizon. A simple test could one day spare people months or years of uncertainty—and make sure they’re getting care that truly matches their condition.